Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Dec;14(12):E84-E94.

Consensus Opinion for The Management of Soft Tissue Filler Induced Vision Loss

Lee Walker  1   2   3   4 , Cormac Convery  1   2   3   4 , Emma Davies  1   2   3   4 , Gillian Murray  1   2   3   4 , Brittony Croasdell  1   2   3   4
Affiliations
Review

Consensus Opinion for The Management of Soft Tissue Filler Induced Vision Loss

Lee Walker et al. J Clin Aesthet Dermatol. 2021 Dec.

Abstract

There are multiple treatment strategies proposed for the management of vision loss related to the injection of soft tissue fillers. Currently, there is no internationally accepted consensus on the immediate management of soft tissue filler induced vision loss (STFIVL). A recent systematic review of the literature concluded that there is not enough evidence to support retrobulbar hyaluronidase, and alternative treatments require exploration. The available literature demonstrates the inconsistent and unproven success of retrobulbar and peribulbar hyaluronidase in reversal of soft filler induced vision loss. Various therapeutics have been used to aid the reversal of vision loss but with mixed outcomes. The current evidence base does not support the use of retrobulbar and peribulbar hyaluronidase. The use of retrobulbar hyaluronidase for reversing soft tissue filler induced vision loss is controversial. Its efficacy remains unproven and there is mixed evidence within the literature. The current evidence suggests that there may be an increased risk of introducing severe adverse events associated with retrobulbar hyaluronidase and may even exacerbate the problem for those clinicians who are not ophthalmology trained. Therefore, we recommend two alternative treatment pathways for ophthalmology and non-ophthalmology trained practitioners. The suggested goal of this publication is to understand the pathophysiology of STFIVL, recognize signs and symptoms, and to propose algorithms to manage vision loss for both non-ophthalmology and ophthalmology trained clinicians. Clinicians must act swiftly and arrange immediate transfer to an emergency department or ophthalmology specialist setting to give the patient the best chance of vision restoration. The focus of any intervention for non-ophthalmology trained clinicians should be based around the immediate use of non-invasive techniques.

Keywords: Vision loss; blindness; central retinal artery; complications; filler; hyaluronic acid; hyaluronidase; ophthalmic artery; ophthalmology; risk, algorithm; soft tissue.

PubMed Disclaimer

Conflict of interest statement

DISCLOSURES: The authors report no conflicts of interest relevant to the content of this article.

Figures

FIGURE 1.
FIGURE 1.
Regions of associated risk of blindness; adapted from Goodman et al
FIGURE 2.
FIGURE 2.
Ophthalmic artery and associated branches
FIGURE 3.
FIGURE 3.
Example of symptoms associated with type IV blindness
None
None
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Goodman GJ, Magnusson MR, Callan P, Roberts S et al. A Consensus on Minimizing the Risk of Hyaluronic Acid Embolic Visual Loss and Suggestions for Immediate Bedside Management. Aesthet Surg J. 2020;40(9):1009–1021. - PMC - PubMed
    1. Beleznay K, Carruthers JDA, Humphrey S et al. Update on avoiding and treating blindness from fillers: a recent review of the world literature. Aesthet Surg J. 2019;39:662–674. - PubMed
    1. Jones DH, Fitzgerald R, Cox SE et al. Preventing and Treating Adverse Events of Injectable Fillers: Evidence-Based Recommendations From the American Society for Dermatologic Surgery Multidisciplinary Task Force. Dermatol Surg. 2021;47(2):214–226. - PubMed
    1. Cho KH, Dalla Pozza E, Toth G et al. Pathophysiology Study of Filler-Induced Blindness. Aesthet Surg J. 2019;39(1):96–106. - PubMed
    1. Khan TT, Colon-Acevedo B, Mettu P et al. An Anatomical Analysis of the Supratrochlear Artery: Considerations in Facial Filler Injections and Preventing Vision Loss. Aesthet Surg J. 2017;37(2):203–208. - PubMed

LinkOut - more resources